Preclinical PET, PET/CT, and PET/MRI

Area of Science:

• Oncology
• Medical Imaging
• Molecular Biology

Background:

• Tumors are a leading cause of death, necessitating a deeper understanding of their molecular progression for improved diagnosis and therapy.
• Radioactive molecules detected by sensitive cameras, particularly in 3D, offer insights into these mechanisms.
• Positron Emission Tomography (PET) utilizes positron-emitting radioisotopes to visualize molecular processes via specific radiotracers.

Purpose of the Study:

• To provide an overview of the diverse applications of preclinical PET in oncology.
• To discuss the challenges associated with preclinical PET in cancer research.
• To highlight the role of preclinical PET in validating novel and existing imaging and therapeutic approaches.

Main Methods:

• Utilizing small animal cancer models for preclinical studies.
• Employing dedicated preclinical PET cameras, often in conjunction with CT or MRI.
• Conducting in vitro experiments to prove tracer specificity before clinical application.

Main Results:

• Preclinical PET has been instrumental in establishing novel imaging, diagnostic, therapy, and theranostic approaches.
• The technology allows for thorough validation of both novel and clinically used radiotracers.
• Integration with CT/MRI enhances the diagnostic and research capabilities of preclinical PET.

Conclusions:

• Preclinical PET is a crucial tool in oncology research for understanding tumor progression.
• It plays a vital role in the development and validation pathway for new cancer diagnostics and therapies.
• Continued advancements in preclinical PET promise further improvements in clinical cancer care.